EE433 Cost-Effectiveness Analysis of a New Second-Line Treatment for Advanced Intrahepatic Cholangiocarcinoma in Taiwan: Genetic Test-Based Targeted Therapy of Pemigatinib Versus Chemotherapy of 5-FU
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.679
https://www.valueinhealthjournal.com/article/S1098-3015(22)02883-2/fulltext
Title :
EE433 Cost-Effectiveness Analysis of a New Second-Line Treatment for Advanced Intrahepatic Cholangiocarcinoma in Taiwan: Genetic Test-Based Targeted Therapy of Pemigatinib Versus Chemotherapy of 5-FU
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02883-2&doi=10.1016/j.jval.2022.09.679
First page :
Section Title :
Open access? :
No
Section Order :
10217